Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.
Lim KJC, Wellard C, Moore E, Ninkovic S, Chng WJ, Spencer A, Mollee P, Hocking J, Ho PJ, Janowski W, Kim K, McCaughan G, Dun K, McQuilten ZK, Chen F, Quach H. Lim KJC, et al. Among authors: mollee p. Clin Lymphoma Myeloma Leuk. 2024 Nov 9:S2152-2650(24)02402-9. doi: 10.1016/j.clml.2024.11.002. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39616008 No abstract available.
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.
Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Huynh K, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, Spencer A, McQuilten ZK. Irving A, et al. Among authors: mollee p. PLoS One. 2024 Aug 27;19(8):e0308812. doi: 10.1371/journal.pone.0308812. eCollection 2024. PLoS One. 2024. PMID: 39190684 Free PMC article.
Variation in immunoglobulin use and impact on survival in myeloma.
Chai KL, Wellard C, Thao L, Aoki N, Moore EM, Augustson BM, Bapat A, Blacklock H, Chng WJ, Cooke R, Forsyth CJ, Goh YT, Hamad N, Harrison SJ, Ho PJ, Hocking J, Kerridge I, Kim JS, Kim K, King T, McCaughan GJ, Mollee P, Morrissey CO, Murphy N, Quach H, Tan XN, Tso AC, Wong KS, Yoon SS, Spencer A, Wood EM, McQuilten ZK. Chai KL, et al. Among authors: mollee p. EJHaem. 2024 Jun 16;5(4):690-697. doi: 10.1002/jha2.938. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157592 Free PMC article.
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
Ho PJ, Moore E, Wellard C, Quach H, Blacklock H, Harrrison SJ, MacDonald EJ, McQuilten ZK, Wood EM, Mollee P, Spencer A. Ho PJ, et al. Among authors: mollee p. Br J Haematol. 2024 Oct;205(4):1337-1345. doi: 10.1111/bjh.19624. Epub 2024 Jul 4. Br J Haematol. 2024. PMID: 38965706
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.
Mollee P, Reynolds J, Janowski W, Quach H, Campbell P, Gibbs S, Lee S, Lee E, Taylor K, Cochrane T, Wallington-Gates C, Kwok F, Weber N, Kerridge I, Weston H, Ho PJ, Leahy MF, Horvath N, Spencer A. Mollee P, et al. Blood Adv. 2024 Jul 23;8(14):3721-3730. doi: 10.1182/bloodadvances.2023012539. Blood Adv. 2024. PMID: 38739707 Free PMC article. Clinical Trial.
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
Ho PJ, Spencer A, Mollee P, Bryant CE, Enjeti AK, Horvath N, Butcher BE, Trotman J, Gibbs S, Joshua DE. Ho PJ, et al. Among authors: mollee p. Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):543-552.e1. doi: 10.1016/j.clml.2024.04.001. Epub 2024 Apr 7. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38702217
2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis.
Bart NK, Fatkin D, Gunton J, Hare JL, Korczyk D, Kwok F, Lam K, Russell D, Sidiqi H, Sutton T, Gibbs SDJ, Mollee P, Thomas L. Bart NK, et al. Among authors: mollee p. Heart Lung Circ. 2024 Apr;33(4):420-442. doi: 10.1016/j.hlc.2023.11.027. Epub 2024 Apr 2. Heart Lung Circ. 2024. PMID: 38570258 Free article.
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.
Ninkovic S, Harrison SJ, Lee JJ, Murphy N, Lee JH, Estell J, Chen VM, Horvath N, Kim K, Eek R, Augustson B, Bang SM, Huang SY, Rajagopal R, Szabo F, Engeler D, Butcher BE, Mollee P, Durie B, Chng WJ, Quach H. Ninkovic S, et al. Among authors: mollee p. Haematologica. 2024 Jul 1;109(7):2229-2238. doi: 10.3324/haematol.2023.284238. Haematologica. 2024. PMID: 38235519 Free PMC article. Clinical Trial.
183 results